Zetta Genomics
Zetta Genomics develops XetaBase, a genomic-native data management and analysis platform that enables clinical diagnostics, healthcare initiatives, biopharmaceutical research, and research institutions to load, normalize, aggregate, index, annotate, filter, visualize, and enrich genomic data at scale. Born from the University of Cambridge and honed through contributions to Genomics England's landmark 100,000 Genomes…
Funding snapshot
About
Zetta Genomics develops XetaBase, a genomic-native data management and analysis platform that enables clinical diagnostics, healthcare initiatives, biopharmaceutical research, and research institutions to load, normalize, aggregate, index, annotate, filter, visualize, and enrich genomic data at scale. Born from the University of Cambridge and honed through contributions to Genomics England's landmark 100,000 Genomes Project, XetaBase is built on the open-source OpenCB software platform. The technology features the most advanced genomic variant database, capable of indexing hundreds of thousands of whole genomes and trillions of variants, replacing slow legacy VCF file analysis methods. Its aggregated variant database scales seamlessly as databases grow, enabling real-time execution of complex queries with results in seconds. XetaBase supports continual re-interpretation of genomic data, unlocking valuable research and clinical insights for precision medicine. Founded in 2018 and headquartered in Cambridge, United Kingdom, the company has raised approximately $10.4 million at the seed stage.
Business model
Life Sciences Tech > Research & Development > Drug Discovery > Genomics > Sequencing Analysis,
Genomics > Genome Informatics > Integrative Bioinformatics Platforms
Institutional investors
Latest coverage
No articles yet.
Similar startups
Immuneel
Developer of T-cell therapies for the treatment of cancer. It is developing cell therapies by using genetic engineering that modifies healthy immune cells to target cancerous cells.
ImmunoACT
Developer of cell and gene therapies for cancer treatment. It offers a lead product NexCAR19 Talicabtagene autoleucel for B‑cell malignancies such as B‑lymphoma and B‑acute lymphoblastic leukaemia.
HaystackAnalytics
EmbeDL is a provider of an edge AI optimization and deployment platform that streamlines the path from deep learning model development to hardware-ready deployment on embedded systems.
4baseCare
Sitehop is a provider of hardware-enforced network encryption solutions that delivers ultra-low latency, quantum-ready encryption for data-in-motion in critical networks through its SAFE Series product line.